Novartis has won FDA approval for Afinitor (everolimus) tablets for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ breast cancer) in combination with exemestane after ...
The US Food and Drug Administration (FDA) has approved Novartis Afinitor (everolimus) to treat patients with non-cancerous kidney tumors associated with tuberous sclerosis complex (TSC). The approval was based on the Phase III ...